Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases.
Angiogenesis is critical for the growth and metastatic spread of tumours. Vascular endothelial growth factor (VEGF) is the most potent inducer of neovasculature, and its increased expression has been related to a worse clinical outcome in many diseases. The purpose of this study was to evaluate the relation between VEGF, its receptors (VEGFR-1 and VEGFR-2) and microvessel density (MVD) in thyroid diseases. Immunostaining for VEGF and VEGF receptors was performed in 66 specimens of thyroid tissue, comprising 17 multinodular goitre (MNG), 14 Graves' disease, 10 follicular adenoma, 8 Hashimoto's thyroiditis, 7 papillary carcinoma and 10 normal thyroid specimens. Thyrocyte positivity for VEGF and VEGF receptors was scored 0-3. Immunohistochemistry for CD31, and CD34 on the same sections was performed to evaluate MVD. Immunohistochemical staining of VEGF in thyrocytes was positive in 92% of all the thyroid tissues studied. Using an immunostaining intensity cut off of 2, increased thyrocyte staining was seen in follicular adenoma specimens, MNG and normal thyroids compared with Hashimoto's thyroiditis and Graves' disease (P < 0.05). Similarly, VEGF thyrocyte expression in Graves' disease was less than other pathologies (P < 0.05). VEGFR-1 expression and the average MVD score did not differ between the different thyroid pathologies. VEGF expression was lower in autoimmune pathologies compared to autonomous growth processes. Conversely, both VEGFR-1 and VEGFR-2 were widely expressed in benign and neoplastic thyroid disease, suggesting that the up-regulation of VEGF and not its receptors occurs as tissue becomes autonomous. There was no clear relationship between MVD measurement and thyroid pathology.
Jebreel
Ala'eddin
A
Department of Otolaryngology, Hull Royal Infirmary, Hull, UK.
England
James
J
Bedford
Karen
K
Murphy
Justin
J
Karsai
Laszlo
L
Atkin
Stephen
S
D006801:Humans; D007124:Immunoenzyme Techniques; D009389:Neovascularization, Pathologic / Q000378:metabolism* / Q000473:pathology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism*; D013959:Thyroid Diseases / Q000378:metabolism*; D013961:Thyroid Gland / Q000098:blood supply* / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000098:blood supply / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism
C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2
Am J Pathol. 1993 Aug;143(2):401-9
7688183
J Endocrinol. 1998 Apr;157(1):5-12
9614352
J Clin Oncol. 1995 Feb;13(2):477-81
7531224
Cancer Res. 1995 Sep 15;55(18):3964-8
7664263
J Natl Cancer Inst. 1995 Nov 1;87(21):1603-12
7563203
Oncogene. 1995 Oct 19;11(8):1569-79
7478581
Breast Cancer Res Treat. 1995;36(2):193-204
8534867
Cancer. 1996 Mar 1;77(5):858-63
8608475
Surgery. 1996 Mar;119(3):333-9
8619189
Mod Pathol. 1996 Jun;9(6):636-41
8782200
J Surg Oncol. 1996 Oct;63(2):95-8
8888801
J Natl Cancer Inst. 1997 Jan 15;89(2):139-47
8998183
Cancer. 1997 Jan 15;79(2):206-13
9010092
Nature. 1997 Apr 17;386(6626):671-4
9109485
J Clin Endocrinol Metab. 1997 Jun;82(6):1968-73
9177415
Br J Cancer. 1997;76(7):930-4
9328154
J Clin Endocrinol Metab. 1997 Nov;82(11):3741-7
9360534
Br J Cancer. 1997;76(9):1221-7
9365173
Am J Surg. 1997 Nov;174(5):513-7
9374227
J Pathol. 1998 Jan;184(1):53-7
9582527
Am J Pathol. 1999 Dec;155(6):1967-76
10595926
Thyroid. 2000 Apr;10(4):349-57
10807064
Hum Pathol. 2000 Apr;31(4):439-42
10821490
J Endocrinol. 2000 Sep;166(3):475-80
11029748
Ann Surg. 2001 Feb;233(2):227-35
11176129
Hum Pathol. 2001 Jan;32(1):10-7
11172289
J Clin Endocrinol Metab. 2001 Feb;86(2):656-8
11158026
IUBMB Life. 2001 Jul;52(1-2):61-6
11795595
Anticancer Res. 2001 Nov-Dec;21(6B):4221-9
11908675
Biol Chem. 2002 Oct;383(10):1573-9
12452433
Cancer Res. 2002 Dec 15;62(24):7284-90
12499271
J Mol Med (Berl). 2003 Jan;81(1):20-31
12545246
Endocrinology. 2004 Feb;145(2):817-22
14605010
Thyroid. 2006 Jun;16(6):545-54
16839256
Endocr Relat Cancer. 2006 Sep;13(3):931-44
16954441
Lancet. 1992 Nov 7;340(8828):1120-4
1279332
J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87
1281237
Endocrinology. 1978 Dec;103(6):2306-14
748050
N Engl J Med. 1991 Jan 3;324(1):1-8
1701519
Endocr Rev. 1992 Feb;13(1):18-32
1372863
Oncol Rep. 1998 Nov-Dec;5(6):1343-8
9769366
J Clin Endocrinol Metab. 1998 Nov;83(11):3908-12
9814467
Am J Surg. 1998 Nov;176(5):442-7
9874430
Eur Urol. 1999 Jan;35(1):2-8
9933788
J Endocrinol. 1999 Apr;161(1):41-9
10194527
Hum Pathol. 1999 Aug;30(8):891-7
10452500
J Thorac Cardiovasc Surg. 1998 May;115(5):1007-14
9605068
J Cancer Res Clin Oncol. 1994;120(11):651-6
7525593